


14th Annual Conference of the
National HIV Nurses Association (NHIVNA)



Dr Sheena McCormack

MRC Clinical Trials Unit, London

14-15 June 2012, Manchester Conference Centre



This house believes that PrEP will
have a major impact on the UK HIV
epidemic

For the motion: **Sheena McCormack**

MRC | Medical Research Council


Two questions

- Does PrEP reduce HIV?
 1. Yes
 2. No
 3. Not sure
- Would PrEP fill a gap in the UK?
 1. Yes
 2. No
 3. Not sure


MRC | Medical Research Council

Two questions

Does PrEP reduce HIV?



Would PrEP fill a gap in the UK?




MRC | Medical Research Council

Biological efficacy

- There is no doubt that Truvada has biological efficacy
 - It stops HIV replication in the lab
 - It protects animals against challenge
 - It reduces HIV in clinical trials

MRC | Medical Research Council

Recent Prevention Trials



PrEP does reduce HIV...by a large amount

- Cases (HIV+), controls (HIV-) **in the Truvada gp**
 - iPrEX:
 - 9% cases, 51% controls = **92% (40-99%)**
 - Partners:
 - 56% cases, 81% controls = **90% (56-98%)**

MRC | Medical Research Council

Adherence

- Biology: minor variation between subjects
- Adherence: huge variation!
- But does it surprise you this happened in the trials when subjects knew they could be on placebo?
 1. Yes
 2. No

MRC | Medical Research Council

Adherence

- Biology: minor variation between subjects
- Adherence: huge variation!
- But does it surprise you this happened in the trials when subjects knew they could be on placebo?

1 **Yes**



2 **No**



MRC | Medical Research Council

Adherence when you know...

- What proportion of people will take drug when they know it will reduce their risk?
 1. 50% as was the case in iPrEX?
 2. 80% as was the case in Partners?

MRC | Medical Research Council

Adherence when you know...

- What proportion of people will take drug when they know it will reduce their risk?

1 **50% as was the case in iPrEX?**




2 **80% as was the case in Partners?**



MRC | Medical Research Council

Efficacy is large for treatment too






Is there a gap to fill?

- Why don't we treat our way out of the epidemic in the UK?

MRC | Medical Research Council

New HIV Diagnoses (Adjusted) - UK





The gap is all about testing...

- *Brown et al*
 - 35% (14,000) of 40,000 MSM were estimated to be infective in 2010, of whom **62% are undiagnosed**, 33% diagnosed but untreated, and 5% on ART.
 - Infective MSM among the diagnosed untreated population fell from 5,200 in 2006 to 4,600 in 2010 with only a modest decline in median VL

MRC | Medical Research Council

The gap is diagnosis...so we need to...

- Engage HIV negative at risk populations
- Tailor HIV testing to frequency of risk
- Tackle barriers to risk reduction
 - Depression
 - Addiction
 - Low self-esteem
- PrEP is an opportunity to make this happen

MRC | Medical Research Council

To conclude

- myprepexperience.com

"Taking the Truvada does not make me "reckless" in my decision to have unprotected sex, it makes me feel supported by a community of doctors and advocates, who recognize the nuances of my situation, and are doing all they can to help me stay negative."

MRC | Medical Research Council

To conclude

- myprepexperience.com

"As I learned the truth about HIV (by becoming an HIV counselor myself and working with young street-based injectors) I started taking more risks myself. At a certain point, I felt like my risk tolerance had the potential to get me infected. So I spent a lot of time considering PrEP. I spoke to doctors, friends working at all levels of prevention and poz men on Truvada. I read up on it and finally decided to try it.

The sex I've had in the last two months has been some of the most spiritual, connected and passionate sex I've ever had. The persistent anxiety I've lived with for so many years is gone."

MRC | Medical Research Council

Acknowledgements

- The participants in all the trials, their partners and communities
- The research teams
- Those who provided slides
 - Valerie Delpech
 - Slim Karim

